Profound exploration of therapeutic approaches targeting the ASC-inflammasome cascade, including immune and stromal cell types as well as the IL-1 superfamily cytokines and their receptors, has recently gained attention and yielded promising data in PSC and IBD research and treatment (Figure 2, Table 1). The gene discussed is IL1A; the disease is inflammatory bowel disease.